On August 13, 2026, the clinical trial titled "Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis" involving teriparatide was listed with a status of completed. The study, registered as NCT07242612, is designated with a phase of not applicable. Teriparatide is an approved compound, and this trial examined bone turnover markers in relation to treatment efficacy among postmenopausal osteoporosis patients.
The trial record reflects a status update to completed as of the date noted, indicating that the study's data collection and associated activities have concluded according to the registry. No results, outcomes, or efficacy data are included in this update. The event data does not specify findings, adverse events, or comparative results, and none should be inferred from the completion status alone.
This brief reflects only the status change recorded for this trial as of the date given. Readers interested in additional context regarding teriparatide can consult the compound overview for further information.